A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma.

Trial Profile

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Evofosfamide (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 03 May 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012.
    • 28 Oct 2011 Results were reported at the Connective Tissue Oncology Society Meeting, according to a Threshold Pharmaceuticals media release.
    • 03 Aug 2011 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top